Proteomic methods for biomarker discovery and validation. Are we there yet?

Noninvasive molecular biomarkers are becoming attractive tools to monitor disease progression, aid drug development programs and use as surrogate outcome measures in clinical trials. Cutting edge proteomic methods to assay biomarkers in body fluids have been developed in the past few years, but transitioning them to clinical practice has been slow and depends on the qualification of both the method and the biomarker.

[1]  Susan E. Abbatiello,et al.  Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach* , 2014, Molecular & Cellular Proteomics.

[2]  Hui Zhang,et al.  Targeted proteomics: a bridge between discovery and validation , 2014, Expert review of proteomics.

[3]  Janne Lehtiö,et al.  Mass spectrometry-based plasma proteomics: state of the art and future outlook , 2014, Expert review of proteomics.

[4]  V. Marx.  Targeted proteomics , 2013, Nature Methods.

[5]  Peter Nilsson,et al.  Systematic antibody and antigen-based proteomic profiling with microarrays , 2011, Expert review of molecular diagnostics.

[6]  Jacob D. Jaffe,et al.  Accurate Inclusion Mass Screening , 2008, Molecular & Cellular Proteomics.

[7]  Kristy Brown,et al.  Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. , 2014, Human molecular genetics.

[8]  J. Mulder,et al.  Affinity proteomic profiling of plasma, cerebrospinal fluid, and brain tissue within multiple sclerosis. , 2014, Journal of proteome research.

[9]  Birgit Schilling,et al.  Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. , 2010, Journal of proteome research.

[10]  R. Ng,et al.  Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry , 2015, Thorax.

[11]  Larry Gold,et al.  Beyond antibodies: New affinity reagents to unlock the proteome , 2014, Proteomics.

[12]  N. Anderson,et al.  The Human Plasma Proteome: History, Character, and Diagnostic Prospects , 2003, Molecular & Cellular Proteomics.

[13]  Stephen A. Williams,et al.  Validation of a blood protein signature for non-small cell lung cancer , 2014, Clinical Proteomics.

[14]  Christoph H Borchers,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[15]  Oliver M. Bernhardt,et al.  Reproducible and Consistent Quantification of the Saccharomyces cerevisiae Proteome by SWATH-mass spectrometry* , 2015, Molecular & Cellular Proteomics.

[16]  Larry Gold,et al.  Advances in human proteomics at high scale with the SOMAscan proteomics platform. , 2012, New biotechnology.

[17]  E. Hoffman,et al.  Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry. , 2012, Journal of bioanalysis & biomedicine.